Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Oncology 40

Oncology

pharma-news-for-biogen-eisai-quidel-accutar-boehringer

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Biogen-Eisai’s Aduhelm; Quidel acquires Ortho Clinical Diagnostics; Accutar Biotechnology’s AC0176; Boehringer’s Spesolimab

Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s approved therapy Aduhelm, which secured a yes under the agency's accelerated review pathway back in June. The decision has proven controversial for Biogen, which has struggled to launch the drug and lately decreased the price to half to catch up on boosting sales. However, Biogen and Eisai have requested the FDA for a similarly accelerated review of lecanema...

Explore More...

Cancer

Snippet

transthyretin amyloidosis

Kalydeco got approved; Opdivo for SCLC; FDA approved for pain relief; GC4419 obviates

cancer

KEY CLINICAL OUTCOMES

Personalised medicine

Personalized Medicine Approach: An Upholding Paradigm for a Promising and futuristic Patient Centric Health Care

Default Blog Image

Sarepta’s deal; Fund raisings for Apexigen; Novo funded rare disease startup

Entasis

Progenics got FDA Approval; Curcumin to cancer cells

Default Blog Image

GeneDx secures $92M funding; BioTech Innovations partners with Novartis for R&D collaboration

Acute lymphoblastic leukemia

Snippet : Acute lymphoblastic leukemia

Therapeutics

Business Cocktail

astellas

Commercial Outcomes – Novartis

MERCK ONCOLOGY

Oncology Highlights – 30/07/2018

acute myeloid leukemia

Predicting risk of Acute Myeloid Leukemia (AML) in healthy individuals

Default Blog Image

NF-κB Inhibitors- A Promising Future

transthyretin amyloidosis

Axovant rely on gene therapy; CAR-T treatments; Pfizer’s dacomitinib; Adaptimmune construct manifestation

Entasis

Business Cocktail

Hematopoietic stem cells

Hematopoietic Stem Cell Transplantation

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly